Klaria Pharma Holding AB (publ.) Valuation
Is KLAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of KLAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: KLAR (SEK0.81) is trading below our estimate of fair value (SEK5.71)
Significantly Below Fair Value: KLAR is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KLAR?
Other financial metrics that can be useful for relative valuation.
What is KLAR's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 105.10m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | -16x |
Enterprise Value/EBITDA | -9.7x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does KLAR's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.5x | ||
RLS RLS Global | 2.1x | 92.8% | SEK 35.6m |
ERMA Enorama Pharma | 6.8x | n/a | SEK 264.9m |
DICOT Dicot Pharma | 7.8x | n/a | SEK 135.4m |
ONCOZ OncoZenge | 5.3x | 119.2% | SEK 75.6m |
KLAR Klaria Pharma Holding AB (publ.) | 5.1x | 57.8% | SEK 105.1m |
Price-To-Book vs Peers: KLAR is good value based on its Price-To-Book Ratio (5.1x) compared to the peer average (6.6x).
Price to Earnings Ratio vs Industry
How does KLAR's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?
Price-To-Book vs Industry: KLAR is expensive based on its Price-To-Book Ratio (5.1x) compared to the Swedish Pharmaceuticals industry average (5x).
Price to Book Ratio vs Fair Ratio
What is KLAR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 5.1x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate KLAR's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.